(E)-2-(3-oxoprop-1-en-1-yl)benzonitrile

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂醛
• 英文名称: (E)-2-(3-oxoprop-1-en-1-yl)benzonitrile
• 英文别名: 2-(3-Oxoprop-1-en-1-yl)benzonitrile；2-[(E)-3-oxoprop-1-enyl]benzonitrile
• 化学式: C₁₀H₇NO
• 分子量: 157.172
• InChiKey: ZYYSASNKIHAOMB-ZZXKWVIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-2-(3-oxoprop-1-en-1-yl)benzonitrile 在 sodium tetrahydroborate 、 溶剂黄146 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium sulfate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 生成 tert-butyl 2-(7-acetyl-9-(2-cyanophenyl)-3-oxo-1H-pyrrolo[3,4-β]indolizin-2(3H)-yl)ethylcarbamate
  参考文献：
  名称：

  Emission Wavelength Prediction of a Full-Color-Tunable Fluorescent Core Skeleton, 9-Aryl-1,2-dihydropyrrolo[3,4-b]indolizin-3-one

  摘要：

  In this paper we report on a novel fluorescent core skeleton, 9-aryl-1,2-dihydropyrrolo[3,4-b]indolizin-3-one, which we named Seoul-Fluor, having tunable and predictable photophysical properties. Using a concise and practical one-pot synthetic procedure, a 68-member library of new fluorescent compounds was synthesized with diverse substituents. In Seoul-Fluor, the electronic characteristics of the substituents, as well as their positional changes, have a close correlation with their photophysical properties. The systematic perturbation of electronic densities on the specific positions of Seoul-Fluor, guided with the Hammett constant, allows emission wavelength tunability covering the full color range. On the basis of these observations and a computational analysis, we extracted a simple first-order correlation of photophysical properties with the theoretical calculation and accurately predicted the emission wavelength of Seoul-Fluors through the rational design. In this study, we clearly demonstrate that Seoul-Fluor can provide a powerful gateway for the generation of desired fluorescent probes without the need for a tiresome synthesis and trial-and-error process.

  DOI：

  10.1021/ja110766a
• 作为产物：
  描述：

  2-烯丙基苯甲腈 在 水 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 10.0h， 以48%的产率得到(E)-2-(3-oxoprop-1-en-1-yl)benzonitrile
  参考文献：
  名称：

  （模块化合成ë）直接从allylarenes -cinnamaldehydes经由无金属DDQ介导的氧化过程†

  摘要：

  通过无金属的DDQ介导的烯丙基芳烃的氧化转化，可以有效合成（E）-肉桂醛。该协议提供了一种实用的方法来制备具有宽泛的官能团耐受性的多种（E）-肉桂醛，并具有良好的优异收率，包括从植物提取物中容易获得天然产物蓝丹醛和香叶基氧基芥子醛。最后，提出了单电子转移过程的机理。

  DOI：

  10.1039/c8ob01469h

文献信息

• Potent Inhibition of Nicotinamide <i>N</i>-Methyltransferase by Alkene-Linked Bisubstrate Mimics Bearing Electron Deficient Aromatics
  作者：Yongzhi Gao、Matthijs J. van Haren、Ned Buijs、Paolo Innocenti、Yurui Zhang、Davide Sartini、Roberto Campagna、Monica Emanuelli、Richard B. Parsons、Willem Jespers、Hugo Gutiérrez-de-Terán、Gerard J. P. van Westen、Nathaniel I. Martin

  DOI：10.1021/acs.jmedchem.1c01094

  日期：2021.9.9

  the development of new bisubstrate inhibitors that include electron-deficient aromatic groups to mimic the nicotinamide moiety. In addition, a trans-alkene linker was found to be optimal for connecting the substrate and cofactor mimics in these inhibitors. The most potent NNMT inhibitor identified exhibits an IC50 value of 3.7 nM, placing it among the most active NNMT inhibitors reported to date. Complementary

  烟酰胺N-甲基转移酶 (NNMT) 将烟酰胺（维生素 B3）甲基化以生成 1-甲基烟酰胺 (MNA)。NNMT 过表达与多种疾病有关，最突出的是人类癌症，表明其作为治疗靶点的潜力。近年来，小分子 NNMT 抑制剂的开发引起了人们的兴趣，其中最有效的抑制剂具有基于烟酰胺底物和S-腺苷-l-甲硫氨酸 (SAM) 辅因子元素的结构特征。我们在这里报告了新的双底物抑制剂的开发，其中包括缺电子的芳族基团来模拟烟酰胺部分。此外，一个跨发现 - 烯烃接头最适合连接这些抑制剂中的底物和辅因子模拟物。鉴定出的最有效的 NNMT 抑制剂的 IC 50值为 3.7 nM，使其成为迄今为止报道的最活跃的 NNMT 抑制剂之一。补充分析技术、建模研究和基于细胞的检测提供了对这些抑制剂的结合模式、亲和力和选择性的深入了解。
• Discovery of Novel Protease Activated Receptors 1 Antagonists with Potent Antithrombotic Activity in Vivo
  作者：Michel Perez、Marie Lamothe、Catherine Maraval、Etienne Mirabel、Chantal Loubat、Bruno Planty、Clemens Horn、Julien Michaux、Sebastien Marrot、Robert Letienne、Christophe Pignier、Arnaud Bocquet、Florence Nadal-Wollbold、Didier Cussac、Luc de Vries、Bruno Le Grand

  DOI：10.1021/jm900553j

  日期：2009.10.8

  Protease activated receptors (PARs) or thrombin receptors constitute a class of G-protein-coupled receptors (GPCRs) implicated in the activation of many physiological mechanisms. Thus, thrombin activates many cell types such as vascular smooth muscle cells, leukocytes, endothelial cells, and platelets via activation of these receptors. In humans, thrombin-induced platelet aggregation is mediated by

  蛋白酶激活受体（PARs）或凝血酶受体构成一类G蛋白偶联受体（GPCR），与许多生理机制的激活有关。因此，凝血酶通过这些受体的活化来活化许多细胞类型，例如血管平滑肌细胞，白细胞，内皮细胞和血小板。在人类中，凝血酶诱导的血小板凝集是由一种称为PAR1的亚型介导的。本文介绍了这些受体的新拮抗剂的发现，更具体地说，发现了两种化合物：2- [5-氧代-5-（4-吡啶-2-基哌嗪-1-基）戊-1,3-二烯基]苄腈36（ F 16618）和3-（2-氯苯基）-1- [4-（4-氟苄基）哌嗪-1-基]丙烯酮39（F 16357），是在优化后获得的。在静脉内或口服给药后，在大鼠的动静脉分流模型中，这两种化合物均能够抑制SFLLR诱导的人血小板聚集并显示抗血栓形成活性。此外，这些化合物没有其他类型的抗血小板药物经常观察到的出血副作用，这构成了这类新型抗血栓药的有希望的优势。
• [EN] COMPOUNDS FOR USE IN CANCER THERAPY<br/>[FR] COMPOSÉS POUR UTILISATION DANS LA THÉRAPIE DU CANCER
  申请人：NUHOPE LLC

  公开号：WO2013024447A1

  公开（公告）日：2013-02-21

  Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.

  提供了用于治疗的方法和组合物，特别是用于治疗癌症，最好是药物耐药性癌症和/或放射线耐药性癌症。这些化合物可用于减小哺乳动物主体的肿瘤大小，并诱导肿瘤细胞凋亡。这些方法对于对于药物如替莫唑胺、多柔比星和格兰达霉素耐药的肿瘤细胞以及非耐药的肿瘤细胞都有效。此外，还提供了用于治疗癌症的巴比妥和硫代巴比妥二烯化合物，以及与这些化合物相关的用途、方法和组合物。
• Barbiturate and thiobarbiturate compounds for use in cancer therapy
  申请人：Connor James R.

  公开号：US09878998B2

  公开（公告）日：2018-01-30

  Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.

  提供了用于治疗的方法和组合物，特别是用于治疗癌症，最好是药物耐药性癌症和/或放射线耐药性癌症。这些化合物可用于减小哺乳动物主体的肿瘤大小，并诱导肿瘤细胞凋亡。这些方法对于对于药物如替莫唑胺、多柔比星和格兰达霉素耐药的肿瘤细胞以及非耐药的肿瘤细胞都有效。此外，还提供了用于治疗癌症的巴比妥和硫代巴比妥二烯化合物，以及与这些化合物相关的用途、方法和组合物。
• Process for preparation of pyridine derivatives
  申请人：Goehring Wolfgang

  公开号：US20050014792A1

  公开（公告）日：2005-01-20

  The present invention relates to a process for the manufacture of compounds of formula wherein the substituents are as described herein which comprises the steps of a) reacting a compound of formula with a compound of formula to form a compound of formula b) converting the OH/═O function of compounds of formula XIV/XIVa into a leaving group P with a reagent containing a leaving group, selected from POCl 3 , PBr 3 , MeI and (F 3 CSO 2 ) 2 O to form a compound of formula wherein P is halogen or trifluoromethanesulfonate; c) substituting R 2 for the leaving group P by reacting compound XV with HR 2 to form a compound of formula and d) hydrolyzing the nitrile function in an acidic medium selected from H 2 SO 4 , HCl and acetic acid, to form a compound of formula I The compounds of formula I are valuable intermediates for the manufacture of therapeutically active compounds which have NK-1 antagonist activity.

  本发明涉及一种制备具有以下公式的化合物的方法，其中取代基如本文所述，包括以下步骤：a)将具有以下公式的化合物与具有以下公式的化合物反应，形成具有以下公式的化合物b)将具有以下公式的化合物的OH/═O功能转化为含有离去基的试剂，所述离去基选自POCl3、PBr3、MeI和(F3CSO2)2O，形成具有以下公式的化合物，其中P为卤素或三氟甲烷磺酸盐；c)通过将化合物XV与HR2反应，用R2替代离去基P，形成具有以下公式的化合物；d)在从H2SO4、HCl和乙酸中选择的酸性介质中水解腈功能，形成具有以下公式的化合物I。公式I的化合物是制备具有NK-1拮抗活性的治疗活性化合物的有价值的中间体。